CureVac (NASDAQ:CVAC - Get Free Report)'s stock had its "hold (c-)" rating restated by analysts at Weiss Ratings in a research note issued to investors on Wednesday,Weiss Ratings reports.
Other equities analysts have also issued reports about the company. Citigroup lowered CureVac to a "market perform" rating in a research report on Thursday, June 12th. Citizens Jmp cut CureVac from a "strong-buy" rating to a "hold" rating in a research report on Thursday, June 12th. UBS Group lowered CureVac from a "strong-buy" rating to a "neutral" rating and cut their price target for the company from $12.00 to $5.50 in a report on Thursday, June 26th. Finally, Jefferies Financial Group restated a "hold" rating and set a $5.00 price objective (down from $7.00) on shares of CureVac in a research report on Friday, June 13th. One equities research analyst has rated the stock with a Buy rating and five have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Hold" and a consensus price target of $6.83.
View Our Latest Analysis on CureVac
CureVac Trading Down 0.2%
Shares of NASDAQ:CVAC traded down $0.01 during midday trading on Wednesday, hitting $5.42. 330,672 shares of the stock were exchanged, compared to its average volume of 415,610. The business's 50-day moving average price is $5.40 and its 200 day moving average price is $4.63. The company has a debt-to-equity ratio of 0.05, a quick ratio of 6.16 and a current ratio of 6.17. The stock has a market capitalization of $1.22 billion, a price-to-earnings ratio of 5.65 and a beta of 2.51. CureVac has a 12 month low of $2.37 and a 12 month high of $5.72.
CureVac (NASDAQ:CVAC - Get Free Report) last posted its quarterly earnings results on Thursday, August 21st. The company reported ($0.30) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.15) by ($0.15). The business had revenue of $1.41 million for the quarter, compared to the consensus estimate of $4.27 million. CureVac had a return on equity of 29.57% and a net margin of 38.21%. Analysts predict that CureVac will post 0.72 earnings per share for the current year.
Institutional Trading of CureVac
Several hedge funds have recently modified their holdings of CVAC. Caitong International Asset Management Co. Ltd raised its stake in shares of CureVac by 354.8% in the second quarter. Caitong International Asset Management Co. Ltd now owns 5,608 shares of the company's stock valued at $30,000 after acquiring an additional 4,375 shares in the last quarter. Greenleaf Trust acquired a new stake in shares of CureVac in the first quarter valued at $31,000. Headlands Technologies LLC acquired a new stake in shares of CureVac in the second quarter valued at $35,000. Integrated Wealth Concepts LLC raised its stake in shares of CureVac by 25.0% in the first quarter. Integrated Wealth Concepts LLC now owns 15,000 shares of the company's stock valued at $42,000 after acquiring an additional 3,000 shares in the last quarter. Finally, Kathmere Capital Management LLC acquired a new stake in shares of CureVac in the second quarter valued at $60,000. 17.26% of the stock is currently owned by institutional investors and hedge funds.
About CureVac
(
Get Free Report)
CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.
Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider CureVac, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CureVac wasn't on the list.
While CureVac currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.